FDA withdrawing proposals
This article was originally published in The Tan Sheet
Executive Summary
GMPs for homeopathic products, "Food Labeling, Nutrient Content Claims & Health Claims" among draft proposals FDA is considering withdrawing, according to 1April 22 Federal Register notice. Agency plans to withdraw 84 proposed rules that have not been finalized, are not considered public health priorities, and which have not received agency action in more than 10 years. "FDA's actions are part of an overall regulatory reform strategy initiated by" HHS Secretary Tommy Thompson, the notice states. Commissioner Mark McClellan, MD/PhD, says action is consistent with agency's commitment to "transparency in its regulatory actions." FDA has included a 2press release and 3FAQ page on its Web site to clear up uncertainties; comments will be accepted through July 21...
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.